- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01915121
An Educational Intervention for Patients With Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer.
Bladder cancer (BL Ca) is the 5th most commonly diagnosed cancer in the US . BL Ca is more common among men than women and 90% of all patients are over the age of 55. Surgery to remove the bladder followed by one of three diversion techniques (i.e., ileal conduit, continent reservoir, and neobladder) is the standard therapy following invasive bladder cancer. The emotional, functional, physical, and social impact of invasive Bl Ca treatment on patients' QOL and adjustment can be devastating. This impact significantly varies by treatment option. Treatment decision making in for BL Ca is difficult at best and potentially susceptible to a number of cognitive and affective factors (e.g., patients' emotional reaction, values, and expectations). Thus, in addition to adjusting to a potential life-threatening disease, having to cope with uncertainty about the efficacy and outcomes of different treatment options adds to the overall distress and may impair effective decision-making. In spite of increasing efforts in health communication and patient education, no study has examined treatment decision making among invasive bladder patients or has provided an educational intervention to facilitate treatment decision making among this population. To this end, and guided by the Self-Regulation theory (SRT) that emphasizes the role of cognitive and emotional factors in decision making, we have designed and pilot tested the acceptability of a preliminary educational and training experiential intervention (ETE) to address this gap in the literature. The ETE intervention uses new and innovative educational strategies and methods to educate patients about their treatment options and to facilitate their treatment decision making.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The goals of the study are: 1) to further enhance the design and application of the ETE intervention, and 2) to provide data on the efficacy of the refined ETE intervention in a randomized-controlled study (RCT). To achieve these 2 goals, the study is divided in to 2 phases.
PHASE 1: To enhance and refine the design and application of the preliminary ETE intervention:
Aim 1-a: To explore knowledge, beliefs, values and expectations about treatment options, treatment decision making, and quality of life (QOL) among patients with BL Ca.
To achieve Aim 1-a of Phase 1, as a first step, 2 focus groups (FG; N = 10 each) of invasive BL Ca patients will be conducted to a) examine knowledge, beliefs, values, expectations, and affective responses about treatment options and treatment decision making, b) record difficulties and problems in post-surgical health care (e.g., using stoma appliances and catheters), and c) explore concerns patients have as they live with the impact of treatment. The ETE intervention will be refined based on FG results.
Aim 1-b: To explore patients' acceptability of the refined ETE intervention. To achieve Aim 1-b of Phase 1, additional 2 FG (FG; N = 10 each) of BL Ca survivors will be conducted to solicit input about the design and acceptability of the refined ETE intervention.
PHASE 2: Aim 2. To assess the efficacy of the ETE intervention in small RCT To achieve Aim 2 of Phase 2, a two-group RCT (standard care (SC) plus time and attention control condition, N = 62 patients; SC plus ETE intervention N = 62 patients) will be conducted to examine the efficacy of the ETE intervention. Phase 2 will provide a) a test of the efficacy of the refined ETE intervention for reducing decisional conflict and regret, and improving QOL and post-treatment stoma and pouch care controlling for potential clinical and socio-demographic covariates (e.g., treatment type, age).
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx, New York, États-Unis, 10468
- James J. Peters VA Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Phase 1 (Focus groups/ In-depth Interview)
Inclusion Criteria:
- treatment of invasive Bladder Cancer a with cystectomy and one of the three major urinary diversion methods
- English speaking
- between the ages of 18 and 85
- able and willing to provide informed consent
- may have received neoadjuvant or adjuvant chemotherapy, radiation therapy, and immunotherapy (BCG)
Exclusion Criteria:
- metastatic disease or cancer recurrence
- presence of other primary cancers
- no access to a telephone
Phase 2 (randomized-controlled-study)
Additional Exclusion Criteria:
- treatment decision is made and /beginning/completion of treatment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Education Intervention
In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
|
1-hour educational and training sessions.
In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended.
Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
|
|
Comparateur placebo: Nutrition Intervention
In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
|
1-hour educational and training sessions.
In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery.
In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended.
Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Decisional Regret Scale
Délai: Baseline
|
The intervention is designed to enhance treatment decision making.
|
Baseline
|
|
Decisional Regret Scale
Délai: 1 month follow up
|
The intervention is designed to enhance treatment decision making.
|
1 month follow up
|
|
Decisional Regret Scale
Délai: 3 month follow up
|
The intervention is designed to enhance treatment decision making.
|
3 month follow up
|
|
Decisional Regret Scale
Délai: 6 month follow up
|
The intervention is designed to enhance treatment decision making.
|
6 month follow up
|
|
Decisional Self-Efficacy Scale
Délai: Baseline
|
The intervention is designed to enhance treatment decision making.
|
Baseline
|
|
Decisional Self-Efficacy Scale
Délai: 1 month follow up
|
The intervention is designed to enhance treatment decision making.
|
1 month follow up
|
|
Decisional Self-Efficacy Scale
Délai: 3 month follow up
|
The intervention is designed to enhance treatment decision making.
|
3 month follow up
|
|
Decisional Self-Efficacy Scale
Délai: 6 month follow up
|
The intervention is designed to enhance treatment decision making.
|
6 month follow up
|
|
Treatment-related Values
Délai: Baseline
|
The intervention is designed to enhance treatment decision making.
|
Baseline
|
|
Treatment-related Values
Délai: 1 month follow up
|
The intervention is designed to enhance treatment decision making.
|
1 month follow up
|
|
Treatment-related Values
Délai: 3 month follow up
|
The intervention is designed to enhance treatment decision making.
|
3 month follow up
|
|
Treatment-related Values
Délai: 6 month follow up
|
The intervention is designed to enhance treatment decision making.
|
6 month follow up
|
|
Decisional Regret Scale
Délai: Baseline
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
Baseline
|
|
Decisional Regret Scale
Délai: 1 month follow up
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
1 month follow up
|
|
Decisional Regret Scale
Délai: 3 month follow up
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
3 month follow up
|
|
Decisional Regret Scale
Délai: 6 month follow up
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
6 month follow up
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
quality of life
Délai: Baseline
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
Baseline
|
|
quality of life
Délai: 1 month follow up
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
1 month follow up
|
|
quality of life
Délai: 3 month follow up
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
3 month follow up
|
|
quality of life
Délai: 6 month follow up
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
6 month follow up
|
|
post-surgical self-care
Délai: Baseline
|
FACT-BL Ca additional concern
|
Baseline
|
|
post-surgical self-care
Délai: 1 month follow up
|
FACT-BL Ca additional concern
|
1 month follow up
|
|
post-surgical self-care
Délai: 3 month follow up
|
FACT-BL Ca additional concern
|
3 month follow up
|
|
post-surgical self-care
Délai: 6 month follow up
|
FACT-BL Ca additional concern
|
6 month follow up
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Délai: Baseline
|
Baseline
|
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Délai: 1 month follow up
|
1 month follow up
|
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Délai: 3 month follow up
|
3 month follow up
|
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Délai: 6 month follow up
|
6 month follow up
|
|
|
Cancer worries scale
Délai: Baseline
|
Baseline
|
|
|
Cancer worries scale
Délai: 1 month follow up
|
1 month follow up
|
|
|
Cancer worries scale
Délai: 3 month follow up
|
3 month follow up
|
|
|
Cancer worries scale
Délai: 6 month follow up
|
6 month follow up
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Nihal E Mohamed, PhD, Icahn School of Medicine at Mount Sinai
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GCO 09-0479
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .